Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters

Database
Language
Document Type
Year range
1.
Viruses ; 14(5)2022 04 28.
Article in English | MEDLINE | ID: covidwho-1875799

ABSTRACT

Randall Cohrs established the Colorado Alphaherpesvirus Latency Society (CALS) in 2011 [...].


Subject(s)
Alphaherpesvirinae , Colorado , Oncogenic Viruses
2.
Virology ; 569: 13-28, 2022 04.
Article in English | MEDLINE | ID: covidwho-1740261

ABSTRACT

Emerging mutations in the SARS-CoV-2 genome pose a challenge for vaccine development and antiviral therapy. The antiviral efficacy of Azadirachta indica bark extract (NBE) was assessed against SARS-CoV-2 and m-CoV-RSA59 infection. Effects of in vivo intranasal or oral NBE administration on viral load, inflammatory response, and histopathological changes were assessed in m-CoV-RSA59-infection. NBE administered inhibits SARS-CoV-2 and m-CoV-RSA59 infection and replication in vitro, reducing Envelope and Nucleocapsid gene expression. NBE ameliorates neuroinflammation and hepatitis in vivo by restricting viral replication and spread. Isolated fractions of NBE enriched in Nimbin isomers shows potent inhibition of m-CoV-RSA59 infection in vitro. In silico studies revealed that NBE could target Spike and RdRp of m-CoV and SARS-CoV-2 with high affinity. NBE has a triterpenoids origin that may allow them to competitively target panoply of viral proteins to inhibit mouse and different strains of human coronavirus infections, suggesting its potential as an antiviral against pan-ß-Coronaviruses.


Subject(s)
Azadirachta , COVID-19 Drug Treatment , Animals , Antiviral Agents/pharmacology , Limonins , Mice , Plant Bark , Plant Extracts/pharmacology , SARS-CoV-2 , Virus Replication
SELECTION OF CITATIONS
SEARCH DETAIL